A solid and technology-driven
foundation for tomorrow's
life sciences, digital health,
or wellness company.

Petra Acquisition Inc. (NASDAQ:PAICU) is a blank check company incorporated in Delaware.


Petra Acquisition was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. We anticipate targeting companies in North America or Europe that are developing assets in the biotech, pharma, medical devices or technology, digital health, and healthcare or wellness sectors.

Management Team

  • Andreas Typaldos
    Andreas Typaldos, CEO
    Chairman of the Board

    A veteran businessman and entrepreneur, especially in the software and technology space where he has been a pioneer founder/early investor of several software and technology companies in the US and Europe, through the Typaldos Family Office. More

  • Sean Fitzpatrick
    Sean Fitzpatrick, CFO
    Board Member

    An experienced capital markets professional, with decades of Wall Street experience at large institutions. The majority of his work experience has focused on the raising and managing of capital from private wealth, family offices, and institutional clients. More

Additional Members of the Board of Directors

  • William Carson
    William Carson
    • Forty-year management experience in drug industry with responsibility for product licensing, new product R&D, manufacturing, acquisitions, and new business entity development.
    • Senior executive and leadership positions at Novartis, Bayer, Galderma
    • Operating roles in medical and regulatory affairs, new product approvals and acquisitions, MTO (Plant Management, New facility Construction, Compliance)
    • BS and MS in Biochemistry and Physiology from University of Nebraska
  • David Dobkin
    David Dobkin
    • Managing Director, LifeSci Capital, a full-service investment bank
    • Chief Financial Officer, LifeSci Acquisition Corp. (Nasdaq:LSAC) and LifeSci Acquisition II Corp. – SPACs focusing on the biotech space
    • Founder, Dobkin & Company, a boutique investment bank
    • Previous investment banking experience at Lazard and Wasserstein Perella
    • B.S. Biomedical Engineering, Columbia, M.S. Biomedical Engineering, USC
  • Anthony Hayes
    Anthony Hayes
    • Chief Executive Officer, AIkido Pharma (Nasdaq:AIKI), f/k/a Spherix, a company focused on technology commercialization
    • Co-founder and managing member, JaNSOME IP Management, an intellectual property management firm
    • American Board of Trial Advocates Young Lawyer of the Year and “20 Under 40” honoree in Columbia, South Carolina
    • B.A. Economics, Mary Washington College, J.D. Tulane University Law School
  • Robert Nicholson
    Robert Nicholson
    • Principal and Managing Director, Archon Private Equity, a private equity and growth capital firm
    • Vice President, Deutsche Bank, Alternative Investments and Private Equity
    • Additional previous buy-side experience at Oxford Financial Group, Wells Real Estate Funds, Cole Capital, and CION Investments, and has worked on joint ventures with funds including Ares and Apollo
    • Former Analyst and Associate at Morgan Stanley
    • B.A. Economics, University of Texas, Austin, M.B.A., Columbia, M.S. Finance, London Business School
  • Sean Fitzpatrick
    Barry Dennis, CFA
    • Managing Director, Investment Banking and Strategic Consulting, WaveCrest Securities
    • President, Strategos Capital Markets Asset Management
    • Senior Managing Director, Structured Products, Canaccord Genuity – served on US ` Executive Management Committee
    • Managing Director, Merrill Lynch, TD Securities, Bank of Montreal
    • Director of LifeSci Acquisition Corp. – SPAC focusing on the biotech space
    • Bachelors of Commerce, University of British Columbia, M.B.A., University of Western Ontario, Holder, Charter of Financial Analysts


5 West 21st Street
New York, NY 10010
Contact Us